PD-L1 Biomarker Testing Market

Rapid technological advances in cancer screening procedures and other major driving factors is expected to favor the rise in the global PD-L1 Biomarker Testing market

 

Reports and Insights has published a new report titled, “PD-L1 Biomarker Testing Market: Opportunity Analysis and Future Assessment 2022-2030

Global PD-L1 Biomarker Testing Market, By Type (22C3 Assay Kit, 28-8 Assay Kit, SP142 Assay Kit, and SP263 Assay Kit), By Indication (Non-small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma, Gastrointestinal Tract Malignancies, Ovarian Cancer, and Hematological Malignancies), By End-User (Hospitals, Diagnostic Laboratories, Specialty Clinics), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2022 and 2030.

In 2021, the U.S. PD-L1 biomarker testing market was accounted for more than US$ 294 Mn

Biomarker can be understood as a molecule of a human body - acquired from body fluids, blood, or tissues - that can be investigated to examine the health of the person. Examining an individual for the existence of diseases via biomarkers and evaluating molecular signs of health is known as biomarker testing. On the same note, PD-L1 can be perceived as a protein whose existence signifies a tumor, surfaced as an early biomarker to be checked in immunotherapy clinical trials. To put it differently, PD-L1 is a protein that holds the role of a “brake” to maintain the body's immune responses under restraint.

PD-L1 is likely to be found on some normal cells and in higher-than-normal quantities on some kinds of cancer cells. The PD-L1 test measures the amount of PD-L1 protein on cancer cells. If an individual’s cancer cells are composed of a higher amount of PDL1, one is likely to benefit from a treatment known as immunotherapy. Immunotherapy is basically a therapy that accelerates an individual’s immune system to assist it in recognizing and fighting against cancer cells.

Rapid diversification in the application of PD-L1 biomarker testing

Cancer research institute (CRI), on November 11, 2020, issued an yearly review, summing up the clinical development of PD-1 and PD-L1 checkpoint inhibitors. In comparison to the initial 2017 report, clinical trials testing PD-1/PD-L1 checkpoint inhibitors have been three folded in just three years to 4,400 clinical trials. Moreover, the former year has witnessed the biggest year-on-year growth with around 1,358 trials supplemented to the landscape between 2019 and 2020. The growth has been headed by compound trials; 90% of the new trials initiated in 2020 are amalgamation strategies.

Further, CRI, on February 10, 2022, issued a year review, summing up the clinical development of PD-1 and PD-L1 checkpoint inhibitors. The count of clinical trials initiated every year that comprise a PD1/PDL1-targeting agent has persisted to increase, at this time at 5,683 all across the world. The ratio of monotherapy (single-agent) PD1/PDL1-blocking drug trials remains to be reduced whilst the count of compound studies is on the surge.

Other than that, according to the investigators at the ASCO Genitourinary Cancers Symposium 2022, the PD-L1 expression is likely to assist in predicting responses to bacillus Calmette-Guérin (BCG) therapy amongst patients with advanced-stage nonmuscle-invasive bladder cancer (NMIBC). In a cohort of 102 BCG-naïve patients, PD-L1 expression was usually low (15%), but higher with growing invasiveness. On multivariate regression, PD-L1 expression was substantially related to 15.1-fold increased odds of response to BCG.

Moreover, Agilent Technologies, Inc., an American analytical instrumentation development and manufacturing company, revealed it has obtained CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to direct alternatives for the first-line treatment of adult patients suffering from HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. As per the company’s statement, “When utilized along with the PD-L1 IHC 28-8 pharmDx as a companion test, treatment with Opdivo in associated with chemotherapy offers the first and only PD-1-directed treatment to reflect excellent entire survival and progression-free survival in comparison to chemotherapy solely.

Reports and Insights Study identifies some of the key participating players in the Agilent Technologies, Inc.. NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., HalioDx, Oxford BioDynamics, and Abcam plc.

About Reports and Insights

Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us

Reports and Insights

Tel: +1-(718)-312-8686

For Sales Query: [email protected]

For New Topics & Other Info: [email protected]





This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK